The spinal cord stimulation market just got a little more crowded with the FDA approval of Nuvectra’s Algovita SCS system.
“We are excited to receive approval from the FDA for the Algovita SCS system,” said Thomas J. Hook, president and CEO of Greatbatch, Inc., (NYSE:GB) which owns Nuvectra. “Algovita’s approval brings to the U.S. market a robust and user-friendly device for patients suffering from chronic pain of the trunk and/or limbs.”
Since 2008, the company has been developing broad-based, neuromodulation technology platforms with a focus on the commercialization of the Algovita SCS system.
The system features a rechargeable implantable pulse generator (the part of the system that is surgically implanted) with 24 independent current sources. The external components feature a wireless Pocket Programmer, a color icon-based charging system, and on-screen battery status indicators.
While goliaths Medtronic (NYSE: MDT), Boston Scientific (NYSE:BSX) and St. Jude (NYSE:STJ) dominate the SCS market, that’s not turning new entries away from the multi-billion dollar industry. In May, newcomer, Nevro (NYSE: NVRO) entered the SCS the market with a novel HF10 high frequency stimulation system in the Senza System.
And, perhaps the newcomers are helping drive the big guys – noting that St. Jude Medical announced FDA approval of its Proclaim Elite recharge-free SCS system just last month.
Spinal cord stimulation (SCS) systems are used for the treatment of chronic intractable pain of the trunk and/or limbs.
One advantage of SCS therapy is that it can be tested out before surgical implantation – called a trial. The trial involves a minor surgical procedure to place a lead along the spinal column that is attached to a temporary stimulator worn outside the body. The trial usually lasts about a week and allows prospective patients to experience the feeling of the therapy, including the level of pain relief it provides.